Research analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of Moderna in a note issued to investors ...

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Morgan Stanley from $70.00 to $38.00 in a report ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Updates 2025 expected revenue range to $1.5 to 2.5 billion Expects ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the developme ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...

Investors in Moderna Inc (Symbol ... publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would ...